Author: Ravi Shankar

Recent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100

DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones.

The latest transactions represent approximately $294,500, with purchases reaching $4.49 per share. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately $563,582 across November 5–11.

Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc’s development story advances.

The CEO Keeps Buying Higher

The latest filing summary details three purchases:

Transaction date	Shares purchased	Reported price
November 10	50,000	$4.192 weighted average
November 11	10,000	$4.49
November 11	10,000	$4.00
Total	70,000	Approximately $4.207 average

The transactions increased Heshmatpour’s reported direct holdings to 3,333,000 shares, separate from his indirectly held positions.

NeOnc previously announced purchases of 80,000 shares across November 5, 6 and 9, totaling approximately $269,082 using personal funds.

The progression stands out. Earlier purchases came in the low-to-mid $3 range. The CEO continued adding above $4, including a transaction at $4.49.

These open-market purchases increase his ownership as investors evaluate the company’s next milestones. Roth MKM also recently reaffirmed its Buy rating and $20 price target, maintaining its bullish valuation.

FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda

On November 11, NeOnc announced that the FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss a potential accelerated approval pathway for intranasal NEO100.

NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for recurrent or progressive IDH-mutant grade 4 astrocytoma.

The company will also seek agreement on NEO100-012, a proposed randomized Phase 3 trial comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint, with the study intended to provide registrational and confirmatory evidence.

NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial. Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.

Two Programs. Several Dates to Watch.

The January meeting adds to an already active calendar:

• November 13: Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation at the Society for Neuro-Oncology Annual Meeting.
• November 17: NeOnc’s FDA End-of-Phase 1 meeting for NEO212 is scheduled to address proposed Phase 2 development and next steps.
• Early January 2027: The newly announced NEO100 meeting will address its potential accelerated approval pathway and proposed Phase 3 trial.

Two investigational drugs, upcoming scientific presentations, separate FDA discussions and continued CEO buying give investors several developments to watch.

A Larger Short Position Adds Potential Fuel

The latest short-interest update puts NTHI at approximately 921,000 shares short as of October 30, compared with 876,682 on October 15.

That represents an increase of roughly 44,000 shares before the stock’s recent advance through $4.

Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at this week’s Society for Neuro-Oncology annual meeting.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.

Recent purchases total 150,000 shares as NeOnc prepares to discuss potential accelerated approval and a Phase 3 confirmatory trial for NEO100

DALLAS, Nov. 12, 2026 (GLOBE NEWSWIRE) — (www.InvestorsTape.com)— NeOnc Technologies Holdings (NASDAQ: NTHI) CEO Amir Heshmatpour has purchased another 70,000 shares in the open market, bringing his recent purchases to 150,000 shares as the company approaches important clinical and regulatory milestones.

The latest transactions represent approximately $294,500, with purchases reaching $4.49 per share. Combined with the preceding 80,000-share purchases announced by NeOnc, Heshmatpour committed approximately $563,582 across November 5–11.

Our bullish interpretation: the CEO continues putting personal capital behind his conviction as NeOnc’s development story advances.

The CEO Keeps Buying Higher

The latest filing summary details three purchases:

Transaction date	Shares purchased	Reported price
November 10	50,000	$4.192 weighted average
November 11	10,000	$4.49
November 11	10,000	$4.00
Total	70,000	Approximately $4.207 average

The transactions increased Heshmatpour’s reported direct holdings to 3,333,000 shares, separate from his indirectly held positions.

NeOnc previously announced purchases of 80,000 shares across November 5, 6 and 9, totaling approximately $269,082 using personal funds.

The progression stands out. Earlier purchases came in the low-to-mid $3 range. The CEO continued adding above $4, including a transaction at $4.49.

These open-market purchases increase his ownership as investors evaluate the company’s next milestones. Roth MKM also recently reaffirmed its Buy rating and $20 price target, maintaining its bullish valuation.

FDA Meeting Puts Phase 3 and Accelerated Approval on the Agenda

On November 11, NeOnc announced that the FDA granted a Type B End-of-Phase meeting scheduled for early January 2027 to discuss a potential accelerated approval pathway for intranasal NEO100.

NeOnc intends to seek feedback on whether its clinical and nonclinical evidence could support an accelerated approval application for recurrent or progressive IDH-mutant grade 4 astrocytoma.

The company will also seek agreement on NEO100-012, a proposed randomized Phase 3 trial comparing NEO100 with investigator-selected standard-of-care chemotherapy. Overall survival would be the primary endpoint, with the study intended to provide registrational and confirmatory evidence.

NeOnc now has an FDA discussion scheduled around a potential approval pathway and the design of a Phase 3 trial. Positive Phase 2a findings provide the foundation for that discussion and give investors a defined next step to follow.

Two Programs. Several Dates to Watch.

The January meeting adds to an already active calendar:

• November 13: Updated NEO100 Phase 1/2a results and NEO212 Phase 1 data are scheduled for presentation at the Society for Neuro-Oncology Annual Meeting.
• November 17: NeOnc’s FDA End-of-Phase 1 meeting for NEO212 is scheduled to address proposed Phase 2 development and next steps.
• Early January 2027: The newly announced NEO100 meeting will address its potential accelerated approval pathway and proposed Phase 3 trial.

Two investigational drugs, upcoming scientific presentations, separate FDA discussions and continued CEO buying give investors several developments to watch.

A Larger Short Position Adds Potential Fuel

The latest short-interest update puts NTHI at approximately 921,000 shares short as of October 30, compared with 876,682 on October 15.

That represents an increase of roughly 44,000 shares before the stock’s recent advance through $4.

Updated NEO100 data and NEO212 Phase 1 findings are scheduled for presentation at this week’s Society for Neuro-Oncology annual meeting.

About InvestorsTape.com

At InvestorsTape.com, our mission is simple: deliver financial news that cuts through the noise and shines a spotlight on the companies, innovations, and market forces shaping the next decade of growth. In a landscape dominated by high-frequency headlines and fleeting narratives, we bring clarity, depth, and balance to the stories that matter, helping investors discover high-potential companies and evaluate emerging opportunities with confidence.

Contact
benh@investorstape.com

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements that may regard NeOnc Technologies Holdings’ future revenue, growth trajectory, profitability outlook, expansion plans, strategic partnerships, potential regulatory approvals, and other projections, plans, and objectives. Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied, including market conditions, timing of venue openings, execution risks, operational performance, competition, regulatory matters, and general economic conditions. Readers should not place undue reliance on these statements, which speak only as of the date made.

General Disclaimer:
InvestorsTape.com has been compensated for press and editorial coverage of NeOnc Technologies Holdings and further disclosure information is available here. This communication is provided for informational and journalistic purposes only and reflects the independent editorial views of InvestorsTape.com.

This editorial discusses investigational therapy and clinical-trial results and is not medical advice or a recommendation to buy or sell securities. This publication is protected speech under the First Amendment of the United States Constitution. Nothing herein constitutes an offer, solicitation, or recommendation to buy or sell any security, nor should it be construed as investment advice. Investing in securities involves risk, including the possible loss of principal. Readers are encouraged to conduct their own due diligence and consult with a qualified financial advisor before making any investment decision.

Executed agreement converts US$3 million of founder loans into restricted Class B ordinary shares in place of cash repayment, bringing total founder debt converted to equity in 2026 to US$11 million and strengthening shareholders’ equity

SINGAPORE, Nov. 12, 2026 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (Nasdaq: TDTH) (“Trident” or the “Company”), a Singapore-headquartered digital infrastructure and technology holding company, today announced that it has executed a Debt Conversion Agreement with its Founder, Chairman and Chief Executive Officer, Soon Huat Lim, and has converted US$3 million of outstanding founder indebtedness into 4,615,384 restricted Class B ordinary shares of the Company.

The conversion removes US$3 million of debt from Trident’s balance sheet without the use of Company cash. The converted amount represents more than half of the approximately US$5 million in working capital loans Mr. Lim had advanced to the Company as of October 31, 2026. Every dollar converted moves from liabilities to shareholders’ equity, preserving cash for operations and growth.

The agreement required no shareholder vote. Upon issuance of the shares, the debt was deemed discharged and paid in full. The shares were issued as restricted securities that have not been registered under the Securities Act of 1933.

A Pattern of Founder Commitment

Today’s announcement extends a consistent record of founder support for Trident in 2026. In July, Mr. Lim converted US$8 million of founder indebtedness into restricted Class B ordinary shares. In October, the Company announced his open-market purchase of Trident shares. With this agreement, total founder debt converted to equity in 2026 reaches US$11 million, and Mr. Lim has again chosen equity in Trident over repayment in cash.

“I have funded this Company because I believe in what we are building, and I am converting that funding into equity because I believe in where it is going,” said Soon Huat Lim, Founder, Chairman and Chief Executive Officer of Trident. “Taking shares instead of cash keeps capital inside the business, strengthens our balance sheet and puts my interests exactly where our shareholders’ interests are. Trident is executing, and I intend to be invested alongside every shareholder as that execution turns into results.”

Stronger Balance Sheet for Execution

A lower debt load and higher shareholders’ equity give Trident greater financial flexibility as it advances its operating platforms. These include TDTHAI, the Company’s enterprise artificial intelligence business; the IRMA Engine Asia joint venture with Digital Innovations Group, covering Asia, the Middle East and Africa; and Trident Aliska Digital Tech Ghana Ltd., which operates the Sikaflow platform and supports the Ghana Revenue Authority digital tax platform launched on June 24, 2026.

Additional details regarding the promissory note and the Debt Conversion Agreement are available in the Company’s Report on Form 6-K filed with the U.S. Securities and Exchange Commission.

About Trident Digital Tech Holdings Ltd

Trident Digital Tech Holdings Ltd is a Singapore-headquartered digital infrastructure holding company focused on building and operating sovereign-scale technology platforms across emerging markets. The Company’s businesses include TDTHAI, its enterprise artificial intelligence platform, and the IRMA Engine Asia joint venture. Through Trident Aliska Digital Tech Ghana Ltd., the Company operates the Sikaflow platform and supports the Ghana Revenue Authority digital tax platform launched on June 24, 2026. For more information, visit https://tridentity.me.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates” and similar expressions, and include statements regarding the issuance of shares under the Debt Conversion Agreement, the expected effect of the conversion on the Company’s balance sheet and shareholders’ equity, and the Company’s business strategy and growth plans. Forward-looking statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. All information in this press release is as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

CONTACT: Public Relations & Global Partnerships:
Phoenix MGMT & Consulting
www.PhoenixMGMTconsulting.com
PR@PhoenixMGMTConsulting.com

Executed agreement converts US$3 million of founder loans into restricted Class B ordinary shares in place of cash repayment, bringing total founder debt converted to equity in 2026 to US$11 million and strengthening shareholders’ equity

SINGAPORE, Nov. 12, 2026 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd (Nasdaq: TDTH) (“Trident” or the “Company”), a Singapore-headquartered digital infrastructure and technology holding company, today announced that it has executed a Debt Conversion Agreement with its Founder, Chairman and Chief Executive Officer, Soon Huat Lim, and has converted US$3 million of outstanding founder indebtedness into 4,615,384 restricted Class B ordinary shares of the Company.

The conversion removes US$3 million of debt from Trident’s balance sheet without the use of Company cash. The converted amount represents more than half of the approximately US$5 million in working capital loans Mr. Lim had advanced to the Company as of October 31, 2026. Every dollar converted moves from liabilities to shareholders’ equity, preserving cash for operations and growth.

The agreement required no shareholder vote. Upon issuance of the shares, the debt was deemed discharged and paid in full. The shares were issued as restricted securities that have not been registered under the Securities Act of 1933.

A Pattern of Founder Commitment

Today’s announcement extends a consistent record of founder support for Trident in 2026. In July, Mr. Lim converted US$8 million of founder indebtedness into restricted Class B ordinary shares. In October, the Company announced his open-market purchase of Trident shares. With this agreement, total founder debt converted to equity in 2026 reaches US$11 million, and Mr. Lim has again chosen equity in Trident over repayment in cash.

“I have funded this Company because I believe in what we are building, and I am converting that funding into equity because I believe in where it is going,” said Soon Huat Lim, Founder, Chairman and Chief Executive Officer of Trident. “Taking shares instead of cash keeps capital inside the business, strengthens our balance sheet and puts my interests exactly where our shareholders’ interests are. Trident is executing, and I intend to be invested alongside every shareholder as that execution turns into results.”

Stronger Balance Sheet for Execution

A lower debt load and higher shareholders’ equity give Trident greater financial flexibility as it advances its operating platforms. These include TDTHAI, the Company’s enterprise artificial intelligence business; the IRMA Engine Asia joint venture with Digital Innovations Group, covering Asia, the Middle East and Africa; and Trident Aliska Digital Tech Ghana Ltd., which operates the Sikaflow platform and supports the Ghana Revenue Authority digital tax platform launched on June 24, 2026.

Additional details regarding the promissory note and the Debt Conversion Agreement are available in the Company’s Report on Form 6-K filed with the U.S. Securities and Exchange Commission.

About Trident Digital Tech Holdings Ltd

Trident Digital Tech Holdings Ltd is a Singapore-headquartered digital infrastructure holding company focused on building and operating sovereign-scale technology platforms across emerging markets. The Company’s businesses include TDTHAI, its enterprise artificial intelligence platform, and the IRMA Engine Asia joint venture. Through Trident Aliska Digital Tech Ghana Ltd., the Company operates the Sikaflow platform and supports the Ghana Revenue Authority digital tax platform launched on June 24, 2026. For more information, visit https://tridentity.me.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements can be identified by words such as “will,” “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates” and similar expressions, and include statements regarding the issuance of shares under the Debt Conversion Agreement, the expected effect of the conversion on the Company’s balance sheet and shareholders’ equity, and the Company’s business strategy and growth plans. Forward-looking statements involve inherent risks and uncertainties, and actual results may differ materially from those expressed or implied. Further information regarding these and other risks is included in the Company’s filings with the U.S. Securities and Exchange Commission, including its annual report on Form 20-F. All information in this press release is as of the date hereof, and the Company undertakes no obligation to update any forward-looking statement, except as required under applicable law.

CONTACT: Public Relations & Global Partnerships:
Phoenix MGMT & Consulting
www.PhoenixMGMTconsulting.com
PR@PhoenixMGMTConsulting.com

ALK will present phase II data from the ALLIANCE trial of its once-daily investigational sublingual immunotherapy (SLIT) tablet for peanut allergy^1,2,3 at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona from 12 to 16 November 2026. The trial included 150 patients aged 4–65 years and evaluated two doses of the tablet compared with placebo.

Key findings being presented include:

• The ALLIANCE phase II trial demonstrated proof-of-concept after only six months of maintenance treatment and efficacy was observed across all age groups in the study.
• Treatment with the peanut tablet was well-tolerated in the study. Treatment-related discontinuations were low. No reports of treatment-related anaphylaxis or treatment-related serious adverse events.

Product Theater: Friday 13 November, 2:35-3:00 PM MT, Product Theater 4
Peanut SLIT-Tablet: A New Frontier in Peanut Allergy Management

Dr. Edwin Kim and Prof. Aikaterini Anagnostou will present recent data from the ALLIANCE trial on the peanut SLIT-tablet and provide insights into the mechanism of action of SLIT in food allergy.

Dr. Jacob Glenting, EVP of Global R&D at ALK, says:

“We’re excited to share the results from the ALLIANCE trial at ACAAI. ALLIANCE provided our first clinical proof of concept for the once-daily sublingual immunotherapy (‘SLIT’) tablet in food allergy. Peanut allergy is a constant presence in the daily life of many patients and their families, and treatment options remain limited. These data give us real momentum as we advance our investigational peanut tablet into phase III, with the goal of offering a sublingual immunotherapy tablet option.”

Dr. Edwin Kim, Division Chief, Pediatric Allergy and Immunology at the University of North Carolina and the principal investigator in the ALLIANCE trial, says:

“We saw a clear dose response in the amount of peanut protein that patients could tolerate after only six months of maintenance treatment, with no treatment-related anaphylaxis or serious adverse events reported. Phase III will be important to build on these results and to understand whether longer treatment can improve response to this once-daily sublingual immunotherapy tablet.”

Scientific Programme
The data are being presented in the following abstracts:

Abstract Title	Presenting Author	Abstract ID ePoster ID	Presentation Details
Efficacy Of The Peanut Sublingual Immunotherapy Tablet In A Phase II Trial	Dr. Edwin Kim	Abstract ID: 8070 ePoster ID: R258	Friday 13 November 4:35-4:50 PM (MT) Monitor 22
Peanut Sublingual Immunotherapy Tablet Was Well Tolerated In A Phase II Trial	Dr. Anna Nowak-Wegrzyn	Abstract ID: 8096 ePoster ID: R252	Friday 13 November 3:05-3:20 PM (MT) Monitor 22
Immunologic Responses Of Peanut-Allergic Individuals To A Peanut Sublingual Immunotherapy Tablet	Dr. Edwin Kim	Abstract ID: 8095 ePoster ID: R250	Friday 13 November 2:35-2:50 PM (MT) Monitor 22

ALK-Abelló A/S

For further information, please contact:

Media: Maiken Riise Andersen, tel. (Denmark) +45 5054 1434
Investor relations: Per Plotnikof, tel. (Denmark) +45 4574 7527, mobile +45 2261 2525

About peanut allergy
Peanut allergy is an IgE-mediated food allergy in which ingestion of peanut proteins triggers immediate hypersensitivity symptoms and can cause anaphylaxis; it typically begins in early childhood and often persists into later life⁴. It is often a severe and potentially life-threatening condition, which accounts for one of the highest rates of anaphylaxis within food allergies^5,6. More than 10 million people in Europe, the USA, and Canada have peanut allergy, more than 3 million of these are children and adolescents^7,8,9. Currently, there are only limited treatment options available, and for some of these patients, sublingual allergy immunotherapy tablets may become a future relevant treatment option with the potential to improve quality of life, both for themselves and their families.

About the ALLIANCE trial
Initiated in 2022, the ALLIANCE trial was designed to assess the tolerability, safety and efficacy of an up-dosing regimen with a once-daily peanut SLIT-tablet in adults, adolescents, and children. The trial was a phase I-II, multi-site trial conducted in North America, with 216 enrolled participants with peanut allergy confirmed by screening via a double-blind, placebo-controlled food challenge. The first part of the trial aimed at determining the starting dose of the up-dosing regimen and the second part aimed at assessing safety and tolerability of the up-dosing regimen as well as gathering early data on its biological action. The third part (phase II) investigated safety and efficacy of selected doses of the peanut SLIT-tablet compared with placebo. The ALLIANCE trial marked the formal start of ALK’s clinical development of a novel food allergy treatment which uses the same technology as ALK’s SLIT-tablets for respiratory allergies.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK’s activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.

Forward-looking statements
This release contains forward-looking statements concerning the development of ALK’s investigational peanut SLIT-tablet, including planned clinical studies and its potential future therapeutic role. These statements reflect current expectations and are subject to risks and uncertainties. Future clinical results may differ from the phase 2 findings, and there can be no assurance that the product will receive regulatory approval or become commercially available.

References 

1. Kim E, Upton J et al. Efficacy Of The Peanut Sublingual Immunotherapy Tablet In A Phase II Trial. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8070.
2.  Nowak-Wegrzyn A, Anagnostou A et al. Peanut Sublingual Immunotherapy Tablet Was Well Tolerated In A Phase II Trial. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8096
3.  Kim E, Chinthrajah S et al. Immunologic Responses Of Peanut-Allergic Individuals To A Peanut Sublingual Immunotherapy Tablet. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8095
4.  Fleischer, David M.; Conover-Walker, Mary Kay; Christie, Lynn; Burks, A. W.; Wood, Robert A. (2003): The natural progression of peanut allergy: Resolution and the possibility of recurrence. In J. Allergy Clin. Immunol. 112 (1), pp. 183–189. DOI: 10.1067/mai.2003.1517.
5.  Cianferoni, Antonella; Muraro, Antonella (2012): Food-induced anaphylaxis. In Immunol. Allergy Clin. North Am. 32 (1), pp. 165–195. DOI: 10.1016/j.iac.2011.10.002.
6.  Pouessel, Guillaume; Beaudouin, E.; Tanno, Luciana K.; Drouet, Martine; Deschildre, Antoine; Labreuche, Julien; Renaudin, Jean-Marie (2019): Food-related anaphylaxis fatalities: Analysis of the Allergy Vigilance Network® database. In Allergy Eur. J. Allergy Clin. Immunol. 74 (6), pp. 1193–1196. DOI: 10.1111/all.13717.
7.  Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in school-aged children in eight European countries—The EuroPrevall-iFAAM birth cohort. Allergy. 2020; 75: 2294–2308
8. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, Nadeau KC. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. Pediatrics. 2018 Dec;142(6):e20181235. doi: 10.1542/peds.2018-1235. Epub 2018 Nov 19. Erratum in: Pediatrics. 2019 Mar;143(3):e20183835. doi: 10.1542/peds.2018-3835. PMID: 30455345; PMCID: PMC6317772.
9. Gupta, Ruchi S.; Warren, Christopher M.; Smith, Bridget M.; Jiang, Jialing; Blumenstock, Jesse A.; Davis, Matthew M. et al. (2019): Prevalence and Severity of Food Allergies Among US Adults. In JAMA network open 2 (1), e185630. DOI: 10.1001/jamanetworkopen.2018.5630.

Attachment

• ALK ACAAI press release_final_121126

ALK will present phase II data from the ALLIANCE trial of its once-daily investigational sublingual immunotherapy (SLIT) tablet for peanut allergy^1,2,3 at the American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Phoenix, Arizona from 12 to 16 November 2026. The trial included 150 patients aged 4–65 years and evaluated two doses of the tablet compared with placebo.

Key findings being presented include:

• The ALLIANCE phase II trial demonstrated proof-of-concept after only six months of maintenance treatment and efficacy was observed across all age groups in the study.
• Treatment with the peanut tablet was well-tolerated in the study. Treatment-related discontinuations were low. No reports of treatment-related anaphylaxis or treatment-related serious adverse events.

Product Theater: Friday 13 November, 2:35-3:00 PM MT, Product Theater 4
Peanut SLIT-Tablet: A New Frontier in Peanut Allergy Management

Dr. Edwin Kim and Prof. Aikaterini Anagnostou will present recent data from the ALLIANCE trial on the peanut SLIT-tablet and provide insights into the mechanism of action of SLIT in food allergy.

Dr. Jacob Glenting, EVP of Global R&D at ALK, says:

“We’re excited to share the results from the ALLIANCE trial at ACAAI. ALLIANCE provided our first clinical proof of concept for the once-daily sublingual immunotherapy (‘SLIT’) tablet in food allergy. Peanut allergy is a constant presence in the daily life of many patients and their families, and treatment options remain limited. These data give us real momentum as we advance our investigational peanut tablet into phase III, with the goal of offering a sublingual immunotherapy tablet option.”

Dr. Edwin Kim, Division Chief, Pediatric Allergy and Immunology at the University of North Carolina and the principal investigator in the ALLIANCE trial, says:

“We saw a clear dose response in the amount of peanut protein that patients could tolerate after only six months of maintenance treatment, with no treatment-related anaphylaxis or serious adverse events reported. Phase III will be important to build on these results and to understand whether longer treatment can improve response to this once-daily sublingual immunotherapy tablet.”

Scientific Programme
The data are being presented in the following abstracts:

Abstract Title	Presenting Author	Abstract ID ePoster ID	Presentation Details
Efficacy Of The Peanut Sublingual Immunotherapy Tablet In A Phase II Trial	Dr. Edwin Kim	Abstract ID: 8070 ePoster ID: R258	Friday 13 November 4:35-4:50 PM (MT) Monitor 22
Peanut Sublingual Immunotherapy Tablet Was Well Tolerated In A Phase II Trial	Dr. Anna Nowak-Wegrzyn	Abstract ID: 8096 ePoster ID: R252	Friday 13 November 3:05-3:20 PM (MT) Monitor 22
Immunologic Responses Of Peanut-Allergic Individuals To A Peanut Sublingual Immunotherapy Tablet	Dr. Edwin Kim	Abstract ID: 8095 ePoster ID: R250	Friday 13 November 2:35-2:50 PM (MT) Monitor 22

ALK-Abelló A/S

For further information, please contact:

Media: Maiken Riise Andersen, tel. (Denmark) +45 5054 1434
Investor relations: Per Plotnikof, tel. (Denmark) +45 4574 7527, mobile +45 2261 2525

About peanut allergy
Peanut allergy is an IgE-mediated food allergy in which ingestion of peanut proteins triggers immediate hypersensitivity symptoms and can cause anaphylaxis; it typically begins in early childhood and often persists into later life⁴. It is often a severe and potentially life-threatening condition, which accounts for one of the highest rates of anaphylaxis within food allergies^5,6. More than 10 million people in Europe, the USA, and Canada have peanut allergy, more than 3 million of these are children and adolescents^7,8,9. Currently, there are only limited treatment options available, and for some of these patients, sublingual allergy immunotherapy tablets may become a future relevant treatment option with the potential to improve quality of life, both for themselves and their families.

About the ALLIANCE trial
Initiated in 2022, the ALLIANCE trial was designed to assess the tolerability, safety and efficacy of an up-dosing regimen with a once-daily peanut SLIT-tablet in adults, adolescents, and children. The trial was a phase I-II, multi-site trial conducted in North America, with 216 enrolled participants with peanut allergy confirmed by screening via a double-blind, placebo-controlled food challenge. The first part of the trial aimed at determining the starting dose of the up-dosing regimen and the second part aimed at assessing safety and tolerability of the up-dosing regimen as well as gathering early data on its biological action. The third part (phase II) investigated safety and efficacy of selected doses of the peanut SLIT-tablet compared with placebo. The ALLIANCE trial marked the formal start of ALK’s clinical development of a novel food allergy treatment which uses the same technology as ALK’s SLIT-tablets for respiratory allergies.

About ALK
ALK is a global specialty pharmaceutical company focused on allergy. ALK’s activities cover the entire value chain of developing, sourcing, producing, and marketing a diversified portfolio of products for diagnosing and treating respiratory allergies and severe allergic reactions (anaphylaxis) in both children and adults. Headquartered in Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen (Nasdaq: ALK B). Visit us at www.alk.net.

Forward-looking statements
This release contains forward-looking statements concerning the development of ALK’s investigational peanut SLIT-tablet, including planned clinical studies and its potential future therapeutic role. These statements reflect current expectations and are subject to risks and uncertainties. Future clinical results may differ from the phase 2 findings, and there can be no assurance that the product will receive regulatory approval or become commercially available.

References 

1. Kim E, Upton J et al. Efficacy Of The Peanut Sublingual Immunotherapy Tablet In A Phase II Trial. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8070.
2.  Nowak-Wegrzyn A, Anagnostou A et al. Peanut Sublingual Immunotherapy Tablet Was Well Tolerated In A Phase II Trial. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8096
3.  Kim E, Chinthrajah S et al. Immunologic Responses Of Peanut-Allergic Individuals To A Peanut Sublingual Immunotherapy Tablet. Poster presentation at the American College of Allergy, Asthma & Immunology (ACAAI) 2026; 12-16 November 2026, Phoenix, Arizona. Abstract 8095
4.  Fleischer, David M.; Conover-Walker, Mary Kay; Christie, Lynn; Burks, A. W.; Wood, Robert A. (2003): The natural progression of peanut allergy: Resolution and the possibility of recurrence. In J. Allergy Clin. Immunol. 112 (1), pp. 183–189. DOI: 10.1067/mai.2003.1517.
5.  Cianferoni, Antonella; Muraro, Antonella (2012): Food-induced anaphylaxis. In Immunol. Allergy Clin. North Am. 32 (1), pp. 165–195. DOI: 10.1016/j.iac.2011.10.002.
6.  Pouessel, Guillaume; Beaudouin, E.; Tanno, Luciana K.; Drouet, Martine; Deschildre, Antoine; Labreuche, Julien; Renaudin, Jean-Marie (2019): Food-related anaphylaxis fatalities: Analysis of the Allergy Vigilance Network® database. In Allergy Eur. J. Allergy Clin. Immunol. 74 (6), pp. 1193–1196. DOI: 10.1111/all.13717.
7.  Grabenhenrich L, Trendelenburg V, Bellach J, et al. Frequency of food allergy in school-aged children in eight European countries—The EuroPrevall-iFAAM birth cohort. Allergy. 2020; 75: 2294–2308
8. Gupta RS, Warren CM, Smith BM, Blumenstock JA, Jiang J, Davis MM, Nadeau KC. The Public Health Impact of Parent-Reported Childhood Food Allergies in the United States. Pediatrics. 2018 Dec;142(6):e20181235. doi: 10.1542/peds.2018-1235. Epub 2018 Nov 19. Erratum in: Pediatrics. 2019 Mar;143(3):e20183835. doi: 10.1542/peds.2018-3835. PMID: 30455345; PMCID: PMC6317772.
9. Gupta, Ruchi S.; Warren, Christopher M.; Smith, Bridget M.; Jiang, Jialing; Blumenstock, Jesse A.; Davis, Matthew M. et al. (2019): Prevalence and Severity of Food Allergies Among US Adults. In JAMA network open 2 (1), e185630. DOI: 10.1001/jamanetworkopen.2018.5630.

Attachment

• ALK ACAAI press release_final_121126

• Among patients previously on long-term prophylaxis (LTP) in HAELO Phase 3 trial, monthly attack rate decreased by 81% following lonvo-z dosing compared with prior LTP
• 100% of patients receiving 50 mg of lonvo-z across Phase 1/2 clinical trial and HAELO were LTP-free as of the data cutoffs
• Among 23 Phase 1/2 patients interviewed, all described their hereditary angioedema (HAE) as well controlled after receiving lonvo-z and 22 (96%) reported lonvo-z as an optimal HAE therapy
• Intellia hosting investor webcast today at 10:00 a.m. ET

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

Oral Presentation Details:

• Title: Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients with Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:43 – 4:53 p.m. MT
  Presenter: Danny Cohn, M.D., Ph.D., Associate Professor, Amsterdam University Medical Center, Department of Vascular Medicine, University of Amsterdam; Phase 1/2 and HAELO principal investigator
  • In the Phase 1/2 study, deep, consistent and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 84% at four weeks that was maintained through up to four years of follow-up. Lonvo-z continues to be well tolerated with no new long-term risks identified.
  • Additional biomarkers were reported that support lonvo-z’s intended mechanism of action in which inactivation of the KLKB1 gene and the associated reduction in plasma kallikrein protein leads to reduced activity of the kallikrein-kinin system and less bradykinin production.
• Title: Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment with Lonvoguran Ziclumeran in Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:53 – 5:03 p.m. MT
  Presenter: Emel Aygören-Pürsün, M.D., Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University; Phase 1/2 and HAELO principal investigator
  • In the Phase 1/2 study (n=32), following a one-time 50 mg dose of lonvo-z, the proportion of patients who were attack-free after one year was at least 90% during each month with up to 4 years of follow-up. Additionally, 100% of patients were LTP-free as of the data cutoff.
  • The estimated probability of beginning an attack-free and LTP-free interval lasting >6 months increased from 81% at six months to 93% at 24 months post-dosing.

Poster Presentation Details: 

• Title: Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:05 – 3:20 p.m. MT
  Presenter: Marc Riedl, M.D., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego; HAELO principal investigator
  • Among the 35 HAELO patients taking LTP at study entry who were randomized to the lonvo-z arm, the mean HAE attack rate decreased by 81% during the efficacy observation period when compared to the attack rate while on prior LTP. Following lonvo-z treatment, 63% of these patients achieved complete control, more than tripling the attack-free rate while on prior LTP.
  • All prespecified subgroups demonstrated consistent benefit in attack rate reduction favoring lonvo-z over placebo regardless of disease severity or prior LTP treatment. All treatment emergent adverse events (TEAEs) were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
• Title: Lived Experiences of Patients Treated with Lonvoguran Ziclumeran, a One-Time CRISPR Treatment for Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:20 – 3:35 p.m. MT
  Presenter: Padmalal Gurugama, MBBS, M.S., M.D., MRCP, FRCPath, Consultant, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust; Phase 1/2 and HAELO principal investigator
  • In interviews with 23 Phase 1/2 patients with a median of 2.4 years of follow-up since lonvo-z infusion, all reported their HAE was well controlled following lonvo-z, compared with 48% before lonvo-z. Among the 23 patients, 86% changed their definition of well controlled post-treatment, describing the shift from symptom management and medication dependence to having no attacks and reduced treatment burden.
  • Of the 23 patients, 22 (96%) described lonvo-z as an optimal therapy, citing its perceived effectiveness and its potential to serve as a one-time treatment that frees them from ongoing preventive treatment.
• Title: Long-Term Prophylaxis for Hereditary Angioedema: Treatment Use, Patterns, and Gaps in a U.S. Claims Database
  Poster Session: Monitor 18
  Date and Time: Friday, November 13, 2026, from 4:05 – 4:20 p.m. MT
  Presenter: Raffi Tachdjian, M.D., M.P.H., Associate Clinical Professor of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of Los Angeles; HAELO principal investigator
  • In a U.S. claims analysis of 538 HAE patients taking LTP over a median of 1.2 years, almost 40% were found to be non-adherent. HAE attacks were similar in both adherent and non-adherent groups, indicating breakthrough attacks despite being on LTP treatment.
• Title: A One-Time Treatment of Lonvoguran Ziclumeran Improves Quality of Life in Patients with Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 4:35 – 4:50 p.m. MT
  Presenter: William Lumry, M.D., Clinical Professor of Internal Medicine, Allergy and Immunology Division, University of Texas Southwestern Medical School, Medical Director, AARA Research Center; HAELO principal investigator
  • HAELO met its key secondary endpoint of change from baseline to week 28 in Angioedema Quality of Life (AE-QoL) total score. Additionally, lonvo-z demonstrated clinically meaningful improvements across all four domains of AE-QoL vs. placebo, with the improvement of quality of life being sustained over time.
  • Patients who received lonvo-z had a 23.5-point mean reduction in AE-QoL total score from baseline to week 28, compared with a 6.5-point mean reduction for placebo. A 6-point reduction on AE-QoL total score is considered to be the threshold for a clinically important difference.
• Title: Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy, Safety, and Tolerability
  Poster Session: Monitor 16
  Date and Time: Friday, November 13, 2026, from 5:35 – 5:50 p.m. MT
  Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Director of Clinical Care, Center for Drug and Vaccine Allergy at Massachusetts General Hospital; HAELO principal investigator
  • Of the 93 patients who received a single one-time 50 mg dose of lonvo-z across the Phase 1/2 and Phase 3 HAELO studies, the overall attack rate reduction from baseline was 89% through up to four years of follow-up, and 97% of patients never initiated LTP after treatment. All patients were LTP-free at the latest follow-up.
  • Favorable safety and tolerability data were observed with the most common (>15% of patients) TEAEs being infusion-related reactions, headache, fatigue and nasopharyngitis. No new long-term risks have been identified.

All presentations will be made available on www.intelliatx.com on the Scientific Publications & Presentations page at the start of the respective sessions.

Investor Webcast Reminder
Intellia will host a live webcast on Thursday, November 12, 2026, at 8:00 a.m. MT / 10:00 a.m. ET to review data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

To join the webcast, visit the Events page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days following the call.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. In September 2026, the FDA accepted the Biologics License Application (BLA) for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.

About Hereditary Angioedema
HAE is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks may still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (also known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologic license application for lonvo-z for the treatment of HAE by the Prescription Drug User Fee Act target action date of March 10, 2027, its expectations regarding any planned U.S. launch of lonvo-z, and the potential of lonvo-z to become the first one-time treatment for HAE and to permanently lower kallikrein by inactivating the KLKB1 gene with a single dose that is administered in an outpatient setting.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

• Among patients previously on long-term prophylaxis (LTP) in HAELO Phase 3 trial, monthly attack rate decreased by 81% following lonvo-z dosing compared with prior LTP
• 100% of patients receiving 50 mg of lonvo-z across Phase 1/2 clinical trial and HAELO were LTP-free as of the data cutoffs
• Among 23 Phase 1/2 patients interviewed, all described their hereditary angioedema (HAE) as well controlled after receiving lonvo-z and 22 (96%) reported lonvo-z as an optimal HAE therapy
• Intellia hosting investor webcast today at 10:00 a.m. ET

CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

Oral Presentation Details:

• Title: Four-Year Durability/Safety of Lonvoguran Ziclumeran (Lonvo-z) 50 mg in Patients with Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:43 – 4:53 p.m. MT
  Presenter: Danny Cohn, M.D., Ph.D., Associate Professor, Amsterdam University Medical Center, Department of Vascular Medicine, University of Amsterdam; Phase 1/2 and HAELO principal investigator
  • In the Phase 1/2 study, deep, consistent and durable reductions in plasma kallikrein were observed in all patients, with a mean reduction of 84% at four weeks that was maintained through up to four years of follow-up. Lonvo-z continues to be well tolerated with no new long-term risks identified.
  • Additional biomarkers were reported that support lonvo-z’s intended mechanism of action in which inactivation of the KLKB1 gene and the associated reduction in plasma kallikrein protein leads to reduced activity of the kallikrein-kinin system and less bradykinin production.
• Title: Attack-Free and Long-Term Prophylaxis-Free Status Following Treatment with Lonvoguran Ziclumeran in Hereditary Angioedema
  Session: Distinguished Industry and Late-Breaking Oral Abstracts – Session 2
  Date and Time: Saturday, November 14, 2026, from 4:53 – 5:03 p.m. MT
  Presenter: Emel Aygören-Pürsün, M.D., Department for Children and Adolescents, Angioedema Centre, University Hospital Frankfurt, Goethe University; Phase 1/2 and HAELO principal investigator
  • In the Phase 1/2 study (n=32), following a one-time 50 mg dose of lonvo-z, the proportion of patients who were attack-free after one year was at least 90% during each month with up to 4 years of follow-up. Additionally, 100% of patients were LTP-free as of the data cutoff.
  • The estimated probability of beginning an attack-free and LTP-free interval lasting >6 months increased from 81% at six months to 93% at 24 months post-dosing.

Poster Presentation Details: 

• Title: Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:05 – 3:20 p.m. MT
  Presenter: Marc Riedl, M.D., Professor of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego; HAELO principal investigator
  • Among the 35 HAELO patients taking LTP at study entry who were randomized to the lonvo-z arm, the mean HAE attack rate decreased by 81% during the efficacy observation period when compared to the attack rate while on prior LTP. Following lonvo-z treatment, 63% of these patients achieved complete control, more than tripling the attack-free rate while on prior LTP.
  • All prespecified subgroups demonstrated consistent benefit in attack rate reduction favoring lonvo-z over placebo regardless of disease severity or prior LTP treatment. All treatment emergent adverse events (TEAEs) were mild or moderate and there were no serious adverse events observed in the lonvo-z arm.
• Title: Lived Experiences of Patients Treated with Lonvoguran Ziclumeran, a One-Time CRISPR Treatment for Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 3:20 – 3:35 p.m. MT
  Presenter: Padmalal Gurugama, MBBS, M.S., M.D., MRCP, FRCPath, Consultant, Clinical Immunology and Allergy, Cambridge University Hospitals NHS Foundation Trust; Phase 1/2 and HAELO principal investigator
  • In interviews with 23 Phase 1/2 patients with a median of 2.4 years of follow-up since lonvo-z infusion, all reported their HAE was well controlled following lonvo-z, compared with 48% before lonvo-z. Among the 23 patients, 86% changed their definition of well controlled post-treatment, describing the shift from symptom management and medication dependence to having no attacks and reduced treatment burden.
  • Of the 23 patients, 22 (96%) described lonvo-z as an optimal therapy, citing its perceived effectiveness and its potential to serve as a one-time treatment that frees them from ongoing preventive treatment.
• Title: Long-Term Prophylaxis for Hereditary Angioedema: Treatment Use, Patterns, and Gaps in a U.S. Claims Database
  Poster Session: Monitor 18
  Date and Time: Friday, November 13, 2026, from 4:05 – 4:20 p.m. MT
  Presenter: Raffi Tachdjian, M.D., M.P.H., Associate Clinical Professor of Medicine and Pediatrics, Division of Allergy and Clinical Immunology, David Geffen School of Medicine, University of Los Angeles; HAELO principal investigator
  • In a U.S. claims analysis of 538 HAE patients taking LTP over a median of 1.2 years, almost 40% were found to be non-adherent. HAE attacks were similar in both adherent and non-adherent groups, indicating breakthrough attacks despite being on LTP treatment.
• Title: A One-Time Treatment of Lonvoguran Ziclumeran Improves Quality of Life in Patients with Hereditary Angioedema
  Poster Session: Monitor 17
  Date and Time: Friday, November 13, 2026, from 4:35 – 4:50 p.m. MT
  Presenter: William Lumry, M.D., Clinical Professor of Internal Medicine, Allergy and Immunology Division, University of Texas Southwestern Medical School, Medical Director, AARA Research Center; HAELO principal investigator
  • HAELO met its key secondary endpoint of change from baseline to week 28 in Angioedema Quality of Life (AE-QoL) total score. Additionally, lonvo-z demonstrated clinically meaningful improvements across all four domains of AE-QoL vs. placebo, with the improvement of quality of life being sustained over time.
  • Patients who received lonvo-z had a 23.5-point mean reduction in AE-QoL total score from baseline to week 28, compared with a 6.5-point mean reduction for placebo. A 6-point reduction on AE-QoL total score is considered to be the threshold for a clinically important difference.
• Title: Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy, Safety, and Tolerability
  Poster Session: Monitor 16
  Date and Time: Friday, November 13, 2026, from 5:35 – 5:50 p.m. MT
  Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Director of Clinical Care, Center for Drug and Vaccine Allergy at Massachusetts General Hospital; HAELO principal investigator
  • Of the 93 patients who received a single one-time 50 mg dose of lonvo-z across the Phase 1/2 and Phase 3 HAELO studies, the overall attack rate reduction from baseline was 89% through up to four years of follow-up, and 97% of patients never initiated LTP after treatment. All patients were LTP-free at the latest follow-up.
  • Favorable safety and tolerability data were observed with the most common (>15% of patients) TEAEs being infusion-related reactions, headache, fatigue and nasopharyngitis. No new long-term risks have been identified.

All presentations will be made available on www.intelliatx.com on the Scientific Publications & Presentations page at the start of the respective sessions.

Investor Webcast Reminder
Intellia will host a live webcast on Thursday, November 12, 2026, at 8:00 a.m. MT / 10:00 a.m. ET to review data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company’s preparations for a planned commercial launch of lonvo-z in HAE.

To join the webcast, visit the Events page of the Investors & Media section of the company’s website at www.intelliatx.com. A replay of the webcast will be available on Intellia’s website for approximately 90 days following the call.

About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an in vivo CRISPR gene editing candidate that is intended to permanently lower kallikrein by inactivating the kallikrein B1 (KLKB1) gene with a single dose that is administered in an outpatient setting. Lonvo-z has received five notable regulatory designations: Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) Designations by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission. In September 2026, the FDA accepted the Biologics License Application (BLA) for lonvo-z and granted Priority Review with a PDUFA target action date of March 10, 2027.

About Hereditary Angioedema
HAE is a rare, genetic disease characterized by severe, recurring and unpredictable inflammatory attacks in various organs and tissues of the body, which can be painful, debilitating and life-threatening. It is estimated that one in 50,000 people are affected by HAE. There are preventative and on-demand treatment options to help manage the condition, including long- and short-term prophylaxis used to prevent swelling attacks. Current treatment options often include lifelong therapies, which may require chronic intravenous (IV) or subcutaneous (SC) administration as often as twice per week or daily oral administration to ensure constant pathway suppression for disease control. Despite chronic administration, breakthrough attacks may still occur. Kallikrein inhibition is a clinically validated strategy for the preventive treatment of HAE attacks.

About Intellia Therapeutics

Intellia Therapeutics, Inc. (Nasdaq: NTLA) is a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.

Forward-Looking Statements

This press release contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements regarding Intellia’s beliefs and expectations concerning: the success and advancement of its program for lonvoguran ziclumeran or “lonvo-z” (also known as NTLA-2002) for the treatment of hereditary angioedema (“HAE”), including its expectations regarding review and approval of its biologic license application for lonvo-z for the treatment of HAE by the Prescription Drug User Fee Act target action date of March 10, 2027, its expectations regarding any planned U.S. launch of lonvo-z, and the potential of lonvo-z to become the first one-time treatment for HAE and to permanently lower kallikrein by inactivating the KLKB1 gene with a single dose that is administered in an outpatient setting.

Any forward-looking statements in this press release are based on management’s current expectations and beliefs of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties related to the conduct of clinical studies and other development and commercialization requirements for its product candidates, including lonvo-z, including risks related to the ability to develop and successfully commercialize lonvo-z or any of Intellia’s product candidates; risks related to Intellia’s ability to protect and maintain its intellectual property position; risks related to Intellia’s relationship with third parties, including its contract manufacturers, collaborators, licensors and licensees; risks related to the ability of its licensors to protect and maintain their intellectual property position; risks related to the results of preclinical studies or clinical studies not being predictive of future results in connection with future studies; the risk that clinical study results will not be positive; and risks related to the potential delay of planned clinical trials due to regulatory feedback or other developments. For a discussion of these and other risks and uncertainties, and other important factors, any of which could cause Intellia’s actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Intellia’s most recent annual report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in Intellia’s other filings with the Securities and Exchange Commission, including its quarterly report on Form 10-Q. All information in this press release is as of the date of the release, and Intellia undertakes no duty to update this information unless required by law.

Investor Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com

Media Contact:
Mike Tattory
Vice President
LifeSci Communications
mtattory@lifescicomms.com

“The Voice of Lowrance” campaign wins Best of Show; Boston Whaler brand refresh and Lowrance Bassmaster Classic also recognized for creative excellence

METTAWA, Ill. , Nov. 12, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), a global leader in recreational marine technology, today announced that its internal creative team received four honors at the 2026 In-House Creativity Awards, presented by the In-House Agency Forum (IHAF). The honors include the competition’s prestigious Best of Show award for Lowrance’s “Voice of Lowrance” campaign.

The awards were presented Nov. 10 at the IHAF Conference & Awards in Boston. The annual In-House Creativity Awards recognize outstanding creative work produced by corporate creative organizations and in-house agencies.

“Lowrance and Boston Whaler are two of the most iconic and storied brands in the marine industry, and continuing to build their legacies requires both a deep respect for their heritage and a willingness to push creative boundaries,” said Lauren Beckstedt, senior vice president and chief marketing officer, Brunswick Corporation. “These awards recognize the passion, imagination and creative excellence our team brings to building meaningful brands and brand experiences. Earning Best of Show is especially rewarding and reflects the exceptional talent we have brought together within Brunswick.”

Brunswick’s 2026 In-House Creativity Awards

• Best of Show, Creative Copywriting: “The Voice of Lowrance,” an integrated advertising campaign celebrating Lowrance’s connection with anglers and fishing culture.
• Gold, Creative Copywriting: “The Voice of Lowrance.”  Watch “The Voice of Lowrance.”
• Silver, Events, B2C, External Audience: Lowrance Bassmaster Classic, recognizing a creative partnership with a local brewery.
• Honorable Mention, Corporate Communications, Brand Identity Kits: Boston Whaler brand refresh, recognizing creative work to modernize the expression of one of the marine industry’s most recognizable brands. Watch the Boston Whaler brand refresh video.

“These awards are a tremendous honor for our entire creative team and a reflection of the talent, dedication and collaboration behind every project,” said Alli Straus, senior director of creative services, Brunswick Corporation. “Our team brings an incredible amount of passion and pride to the work, and having that creativity recognized by our peers in the industry is especially meaningful. It’s a testament to what we can accomplish when talented people come together around a shared commitment to great ideas and exceptional execution.”

The In-House Creativity Awards recognize outstanding creative work produced by internal agencies across more than 40 categories, including advertising, corporate identity, social media, video and experiential marketing. Entries are evaluated by a panel of industry experts, with Gold, Silver and Honorable Mention awards presented across individual categories and a single Best of Show honor awarded across the competition.

The four honors highlight Brunswick’s investment in building marketing and creative capabilities internally, combining brand expertise with creative innovation to strengthen consumer connections across its portfolio.

About Brunswick

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion, parts and accessories, marine electronics, as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. For more information, visit Brunswick.com or the Brunswick Newsroom

###

CONTACT: Brad Carroll
Director, External Enterprise Communication
734-751-3088
bradley.carroll@brunswick.com 

“The Voice of Lowrance” campaign wins Best of Show; Boston Whaler brand refresh and Lowrance Bassmaster Classic also recognized for creative excellence

METTAWA, Ill. , Nov. 12, 2026 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC), a global leader in recreational marine technology, today announced that its internal creative team received four honors at the 2026 In-House Creativity Awards, presented by the In-House Agency Forum (IHAF). The honors include the competition’s prestigious Best of Show award for Lowrance’s “Voice of Lowrance” campaign.

The awards were presented Nov. 10 at the IHAF Conference & Awards in Boston. The annual In-House Creativity Awards recognize outstanding creative work produced by corporate creative organizations and in-house agencies.

“Lowrance and Boston Whaler are two of the most iconic and storied brands in the marine industry, and continuing to build their legacies requires both a deep respect for their heritage and a willingness to push creative boundaries,” said Lauren Beckstedt, senior vice president and chief marketing officer, Brunswick Corporation. “These awards recognize the passion, imagination and creative excellence our team brings to building meaningful brands and brand experiences. Earning Best of Show is especially rewarding and reflects the exceptional talent we have brought together within Brunswick.”

Brunswick’s 2026 In-House Creativity Awards

• Best of Show, Creative Copywriting: “The Voice of Lowrance,” an integrated advertising campaign celebrating Lowrance’s connection with anglers and fishing culture.
• Gold, Creative Copywriting: “The Voice of Lowrance.”  Watch “The Voice of Lowrance.”
• Silver, Events, B2C, External Audience: Lowrance Bassmaster Classic, recognizing a creative partnership with a local brewery.
• Honorable Mention, Corporate Communications, Brand Identity Kits: Boston Whaler brand refresh, recognizing creative work to modernize the expression of one of the marine industry’s most recognizable brands. Watch the Boston Whaler brand refresh video.

“These awards are a tremendous honor for our entire creative team and a reflection of the talent, dedication and collaboration behind every project,” said Alli Straus, senior director of creative services, Brunswick Corporation. “Our team brings an incredible amount of passion and pride to the work, and having that creativity recognized by our peers in the industry is especially meaningful. It’s a testament to what we can accomplish when talented people come together around a shared commitment to great ideas and exceptional execution.”

The In-House Creativity Awards recognize outstanding creative work produced by internal agencies across more than 40 categories, including advertising, corporate identity, social media, video and experiential marketing. Entries are evaluated by a panel of industry experts, with Gold, Silver and Honorable Mention awards presented across individual categories and a single Best of Show honor awarded across the competition.

The four honors highlight Brunswick’s investment in building marketing and creative capabilities internally, combining brand expertise with creative innovation to strengthen consumer connections across its portfolio.

About Brunswick

Brunswick Corporation (NYSE: BC) is a global leader in marine recreation, delivering innovation that transforms experiences on the water and beyond. Its technology-driven solutions are informed by deep consumer insights and guided by the belief that “Next Never Rests™.” Brunswick is home to more than 60 industry-leading brands across marine propulsion, parts and accessories, marine electronics, as well as boat brands including Boston Whaler, Sea Ray, Bayliner, Lund and Harris. Headquartered in Mettawa, Illinois, Brunswick has approximately 14,000 employees operating in 26 countries. For more information, visit Brunswick.com or the Brunswick Newsroom

###

CONTACT: Brad Carroll
Director, External Enterprise Communication
734-751-3088
bradley.carroll@brunswick.com